Antiphospholipid antibody syndrome secondary to trimethoprim/ sulfamethoxazole

Journal of Drugs in Dermatology

Volumn 11, Issue 9, 2012, Pages 1117-1118

  Silverberg, Jonathan I ^a   Votava, Henry J ^a   Smith, Barry L ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CEFALEXIN; COTRIMOXAZOLE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PREDNISONE;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING DISORDER; CASE REPORT; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HEMOLYTIC ANEMIA; HUMAN; HYPERTRANSAMINASEMIA; LEG ULCER; MALAISE; THROMBOCYTOPENIA;

ANTI-INFECTIVE AGENTS; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; THROMBOSIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84867472433     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Asherson RA, Mayou SC, Merry P, Black MM, Hughes GR. The spectrum of livedo reticularis and anticardiolipin antibodies. Br J Dermatol. 1989;120:215-21. (Pubitemid 19055423)
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
3. Lim W, Crowther MA, Eikelboom JW. Management of Antiphospholipid Antibody Syndrome. JAMA. 2006;295:1050-1057.
4. Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67:195-205. (Pubitemid 351183308)
5. Asherson R, Cervera R, Khamashta MA, Reverter JC, Cervera R, A. Khamashta M. Antiphospholipid Syndrome in Systemic Autoimmune Diseases. Handbook of Systemic Autoimmune Diseases Ser. San Diego: Elsevier Science Imprint Elsevier Science & Technology Books, 2009:144.
6. Petri M, Allbritton J. Antibiotic allergy in systemic lupus erythematosus: a case-control study. J Rheumatol. 1992;19:265-269.
7. Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis. 2003;62:388-393. (Pubitemid 36469726)
8. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci. 2007;1108:166-182. (Pubitemid 47528730)
9. Canoso RT, Sise HS. Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities. Am J Hematol. 1982;13:121-129. (Pubitemid 12009556)
10. Zarrabi MH, Zucker S, Miller F, Derman RM, Romano GS, Hartnett JA, et al. Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med. 1979;91:194-199. (Pubitemid 10172176)
11. Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med. 1980;92:156-159. (Pubitemid 10141570)
12. Blumenkrantz N, Christiansen AH, Ullman S, Asboe-Hansen G. Hydrala-zine-induced Lupoid syndrome. Biochemical and immunological studies. Acta Med Scand. 1974;195:443-449.
13. Irias JJ. Hydralazine-induced lupus erythematosus-like syndrome. Am J Dis Child. 1975;129:862-864.
14. Lee SL, PH CH. Drug-induced systemic lupus erythematosus: a critical review. Semin Arthritis Rheum. 1975;5:83-103.
15. Blomgren SE, Condemi JJ, Bignall MC, Vaughan JH. Antinuclear antibody induced by procainamide. A prospective study. N Engl J Med. 1969; 281:64-66.
16. Ortiz GA, Lagari-Libhaber V, Prieto-Sanchez LM, Rabinstein AA. Propylthio-uracil-induced lupus, antiphospholipid syndrome, and stroke in a patient with Graves hyperthyroidism. Arch Neurol. 2011;68:1587-1590.